---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic impact on families"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic impact on families. Topics: Caregiver time, transportation, and household tasks: United States caregiver survey; Caregiver employment and out-of-pocket spending: United States caregiver survey; Caregiver burden scores and their association with patient vision-related quality of life; Caregiver share of productivity costs: United States cost-of-illness estimate for late AMD; 2 further topics. 6 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description/economic-impact-on-families"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic impact on families

<a id="heading-2.2.1.8.3"></a>

## 2.2.1.8.3 Economic Impact of Geographic atrophy secondary to age-related macular degeneration on Families

<a id="topic-2.2.1.8.3-1"></a>

### Caregiver time, transportation, and household tasks: United States caregiver survey

> “Eighty-three percent (83%) of caregivers reported having to drive patients to their eye appointments for GA and 76% reported having to drive patients to other medical appointments.”
> “Caregivers reported spending a median time of 10 (interquartile range: 5–25) hours per week on household tasks that the patients would have been able to perform independently if not for their visual impairment due to GA.”
> “Caregivers reported having provided support for a mean (SD) of 3.3 (4.7) years to the patient with GA they cared for, and 81% of caregivers reported living with the person they cared for.”

Source: [Bakri et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11348935/)

<a id="topic-2.2.1.8.3-2"></a>

### Caregiver employment and out-of-pocket spending: United States caregiver survey

> “A relatively high proportion of caregivers (41%) had a change in their employment status after becoming a caregiver, with 50% of them unable to work due to caregiving; 29% reported working fewer hours, and 12% retired early.”
> “Patients and caregivers reported using their own money to purchase products to assist the patient with GA, including items such as extra lighting (63% and 52%, respectively), eyeglasses (72% and 51%, respectively) or devices to assist with reading (64% and 50%, respectively).”
> “Patients and caregivers also reported significant financial burden, with 44% of patients and 37% of caregivers being concerned or very concerned about the effect of GA on their finances in the future.”

Source: [Bakri et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11348935/)

<a id="topic-2.2.1.8.3-3"></a>

### Caregiver burden scores and their association with patient vision-related quality of life

> “Regarding caregivers, mean (SD) ZBI total score was 24.8 (18.7) on a scale ranging from 0 to 88, in which higher score indicates more severe burden.”
> “Overall, Spearman rank-order correlation coefficients between NEI VFQ-39 subscale and composite scores and ZBI total score ranged from −0.63 to −0.21, indicating a correlation between vision-related QoL of the patient and the caregiver’s burden.”

Source: [Bakri et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11348935/)

<a id="topic-2.2.1.8.3-4"></a>

### Caregiver share of productivity costs: United States cost-of-illness estimate for late AMD

> “In GA, 88% of the total cost incurred due to the loss of productivity resulted from the impact on patients, while the remaining 12% of the cost was attributable to the impact on caregivers.”
> “However, in the US, particularly for GA, a sizeable proportion of productivity cost (12%) was attributed to caregivers’ loss of productivity.”
> “Productivity costs accounted for the loss of productivity and employment changes for patients and caregivers. Parameters included patient job loss, patient job reduction, caregiver job reduction due to caregiving responsibilities, caregiver job reduction due to providing transport to eye health care appointments, and caregiver loss of leisure time due to providing transport.”

Source: [Paudel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12316190/)

<a id="topic-2.2.1.8.3-5"></a>

### Costs to patients and caregivers: systematic literature review

> “Patients and caregivers incur out-of-pocket costs; for US patients, these included vision aids such as magnifying systems, flashlights, or talking watches. Caregivers usually provided transportation and helped with household chores.5 A US retrospective cohort study of administrative claims data (n = 14,421) from 2015 to 2018 determined the mean cost to the patient with GA to be $2863 (adjusted to 2020 USD).”
> “In addition, very little information was identified on the humanistic effect on caregivers.”

Source: [Sarda et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8667751/)

<a id="topic-2.2.1.8.3-6"></a>

### Travel companions and informal care

> “Most patients with GA reported regularly traveling with a partner or friend.”

Source: [Patel et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6955611/)

> “It is clear that support, whether through informal or structured care, is vital to the wellbeing of people with GA. Despite this, the general public are often unaware of care work, which may result in this integral role being undervalued and under acknowledged.”

Source: [Caswell et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8319273/)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
